$0.068
-0.033 (-48.48%)收盘时
- High
- 0.133
- Open
- 0.129
- VWAP
- 0.09
- Vol
- 1.31M
- Mkt Cap
- —
- Low
- 0.058
- Amount
- 113.35K
- EV/EBITDA, TTM
- 0.00
Scorpius Holdings, Inc., formerly NightHawk Biosciences, Inc., is an integrated contract development and manufacturing company. The Company is focused on advancing biologic and cell therapy programs to the clinic and beyond. It offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas. Its analytical services include development of a comprehensive range of analytical test methods to characterize complex biologics, including cell therapy-based products, protein therapeutics, vaccines and advanced therapies. Its Clinical Biomanufacturing includes cGMP Mammalian Cell Culture, and cGMP Microbial Fermentation. Its San Antonio facility is focused on the commercial-scale manufacturing of biodefense-focused molecules and biologics therapeutics. Its biomanufacturing services focus on accelerating product development timelines from pre-clinical evaluation to first-in-human studies.
估值指标
事件时间线
资讯
4.504-22BenzingaCrude Oil Gains 3%; 3M Posts Better-Than-Expected Q1 Results
2.004-22BenzingaDow Jumps Over 400 Points; Verizon Earnings Top Views
7.004-22SeekingAlphaScorpius Holdings gets NYSE American delisting notice, plans to appeal
7.004-01NASDAQ.COMScorpius Holdings, Inc. Faces Delisting Proceedings from NYSE American Due to Noncompliance
8.502-26NewsfilterScorpius Holdings Engages Alliance Global Partners to Explore Strategic Alternatives
SCPX FAQ — answered by Alphio AI
Scorpius Holdings, Inc., formerly NightHawk Biosciences, Inc., is an integrated contract development and manufacturing company. The Company is focused on advancing biologic and cell therapy programs to the clinic and beyond. It offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas. Its analytical services include development of a comprehensive range of analytical test methods to characterize complex biologics, including cell therapy-based products, protein therapeutics, vaccines and advanced therapies. Its Clinical Biomanufacturing includes cGMP Mammalian Cell Culture, and cGMP Microbial Fermentation. Its San Antonio facility is focused on the commercial-scale manufacturing of biodefense-focused molecules and biologics therapeutics. Its biomanufacturing services focus on accelerating product development timelines from pre-clinical evaluation to first-in-human studies. It operates in the Healthcare sector.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。